IL312221A - Heterodimeric fc cytokines and uses thereof - Google Patents

Heterodimeric fc cytokines and uses thereof

Info

Publication number
IL312221A
IL312221A IL312221A IL31222124A IL312221A IL 312221 A IL312221 A IL 312221A IL 312221 A IL312221 A IL 312221A IL 31222124 A IL31222124 A IL 31222124A IL 312221 A IL312221 A IL 312221A
Authority
IL
Israel
Prior art keywords
heterodimeric cytokines
heterodimeric
cytokines
Prior art date
Application number
IL312221A
Other languages
English (en)
Hebrew (he)
Inventor
Patrick J Lupardus
Deepti Rokkam
Original Assignee
Synthekine Inc
Patrick J Lupardus
Deepti Rokkam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthekine Inc, Patrick J Lupardus, Deepti Rokkam filed Critical Synthekine Inc
Publication of IL312221A publication Critical patent/IL312221A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5425—IL-9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL312221A 2021-10-20 2022-10-20 Heterodimeric fc cytokines and uses thereof IL312221A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163257913P 2021-10-20 2021-10-20
PCT/US2022/078465 WO2023070056A2 (en) 2021-10-20 2022-10-20 Heterodimeric fc cytokines and uses thereof

Publications (1)

Publication Number Publication Date
IL312221A true IL312221A (en) 2024-06-01

Family

ID=86059699

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312221A IL312221A (en) 2021-10-20 2022-10-20 Heterodimeric fc cytokines and uses thereof

Country Status (11)

Country Link
US (2) US12522639B2 (enExample)
EP (1) EP4419545A4 (enExample)
JP (1) JP2024539139A (enExample)
KR (1) KR20240099287A (enExample)
CN (1) CN118451096A (enExample)
AU (1) AU2022369312A1 (enExample)
CA (1) CA3234552A1 (enExample)
IL (1) IL312221A (enExample)
MX (1) MX2024004763A (enExample)
WO (1) WO2023070056A2 (enExample)
ZA (1) ZA202403036B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
WO2024018369A1 (en) * 2022-07-18 2024-01-25 Onko-Innate Pty Ltd Il-12 fc fusion proteins and uses thereof
CN121152798A (zh) * 2023-05-12 2025-12-16 新叶生维(英国)有限公司 分泌特异性降效细胞因子il-12的car t细胞
WO2025012105A2 (en) * 2023-07-07 2025-01-16 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Muteins of human interleukin 12
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5573764A (en) 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US7282204B2 (en) 2003-03-10 2007-10-16 Schering Corporation Uses of IL-23 agonists and antagonists; related reagents
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8802643B1 (en) 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CN103145842A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
PL1966238T3 (pl) 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
MX387323B (es) 2014-02-19 2025-03-18 Merck Patent Gmbh Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer.
EP3197911A4 (en) 2014-09-22 2018-06-20 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US11087249B2 (en) 2016-05-24 2021-08-10 Ciambella Ltd. Method and apparatus for triggering execution of a workflow over a network
US10696722B2 (en) * 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SE541511C2 (sv) 2017-03-06 2019-10-22 Slaettberg Fredrik Installationsklara vägg- och regelkassetter
CN110101843A (zh) 2018-02-01 2019-08-09 北京科诺科服生物科技有限公司 一种抗肿瘤蛋白质及其应用
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
SG11202104136YA (en) 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
BR112022001320A2 (pt) 2019-07-25 2022-04-12 Univ Chicago Composições e métodos compreendendo agentes terapêuticos ativados por protease
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
CA3166009A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Il2 muteins
WO2021146436A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
CN115916261A (zh) 2020-04-17 2023-04-04 小利兰·斯坦福大学董事会 工程化il-12和il-23多肽及其用途
MX2022013112A (es) 2020-04-22 2023-01-16 Dragonfly Therapeutics Inc Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc.
EP4334337A2 (en) 2021-05-05 2024-03-13 Ankyra Therapeutics, Inc. Fusion polypeptides
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
WO2023070038A2 (en) * 2021-10-20 2023-04-27 Synthekine, Inc. Human il-12p40 variants and uses thereof

Also Published As

Publication number Publication date
AU2022369312A1 (en) 2024-05-02
CN118451096A (zh) 2024-08-06
EP4419545A4 (en) 2025-10-22
KR20240099287A (ko) 2024-06-28
US12522639B2 (en) 2026-01-13
CA3234552A1 (en) 2023-04-27
EP4419545A2 (en) 2024-08-28
ZA202403036B (en) 2025-08-27
WO2023070056A2 (en) 2023-04-27
JP2024539139A (ja) 2024-10-28
US20240132562A1 (en) 2024-04-25
MX2024004763A (es) 2024-05-08
US20240209049A1 (en) 2024-06-27
US12103954B2 (en) 2024-10-01
WO2023070056A3 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
IL312221A (en) Heterodimeric fc cytokines and uses thereof
EP3854805A4 (en) NOVEL INTERLEUKIN 2 AND ITS USE
EP3854806A4 (en) NOVEL INTERLEUKIN 2 AND ITS USE
EP4444290A4 (en) STAT3 DEGRADING AGENTS AND THEIR USES
IL283217A (en) Split interleukin mimetics and their use
EP3810172A4 (en) Heterodimeric proteins and uses thereof
DK3511340T3 (da) Heterodimerisk fc-fusioneret cytokin og farmaceutisk sammensætning omfattende det samme
IL292692A (en) Mrgprx2 antagonists and uses thereof
DK4140297T3 (da) Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf
DK3743418T3 (da) Chemokinreceptormodulatorer og anvendelser deraf
EP3453401A4 (en) INTERLEUKIN COMBINATION AND USE THEREOF
EP3720470A4 (en) IL-2 MUTEINS AND THEIR USES
PL3917626T3 (pl) Dwutrybowy radioznacznik i terapeutyk wiążący psma
EP4353249A4 (en) MULTI-AGONIST AND ITS USE
EP3814385A4 (en) SIRPALPHA-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
DK3743088T3 (da) IL-22 Fc-sammensætninger og fremgangsmåder til anvendelse
EP3939242A4 (en) MOBILE PEER-TO-PEER NETWORKS AND RELATED APPLICATIONS
EP4514954A4 (en) NEW CRISPR-CAS12I SYSTEMS AND THEIR USES
IL292693A (en) Mrgprx2 antagonists and uses thereof
EP3985427A4 (en) LENS AND HEAD MOUNT DISPLAY
EP4305160A4 (en) NEW CRISPR-CAS12I SYSTEMS AND THEIR USES
EP3741758A4 (en) BROMODOMAIN INHIBITOR COMPOUND AND ITS USE
DK3908570T3 (da) Ketaminpamoat og andevendelse deraf
EP4405487A4 (en) IL-2 VARIANTS AND THEIR FUSING PROTEINS
EP4136101A4 (en) GENETICALLY MODIFIED INTERLEUKIN-22 POLYPEPTIDES AND THEIR USES